BioSpace News Archive

Business

Shineco, Inc. Intends to Acquire a Controlling Interest of Xiang Peng You Kang (Beijing) Technology Co., Ltd., a Healthcare Services Company

Shineco, Inc. announced that on November 18, 2021, it entered into non-binding framework agreements (the “Framework Agreements”) with certain shareholders of Xiang Peng You Kang (Beijing) Technology Co., Ltd.

December 3, 2021
·
7 min read
AstraZeneca Canada Named a Greater Toronto Top Employer for Eighth Straight Year

AstraZeneca Canada, a leading innovation-driven biopharmaceutical company, has been selected for the eighth consecutive year as one of Greater Toronto’s Top Employers.

December 3, 2021
·
2 min read
Next Generation Implants Market to Reach Valuation of USD 4.45 Billion by 2028 Growing at a CAGR of 3.2%, according to Emergen Research

The global next generation implants market is expected to reach a market size of USD 4.45 Billion in 2028 and register a steady CAGR over the forecast period, according to latest analysis by Emergen Research.

December 3, 2021
·
5 min read
Drug Development

UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics Ltd. is pleased to announce that the Company has decided to expand research with Bucillamine, an oral drug shown to have promising anti-viral and anti-inflammatory capabilities and is being evaluated in a current Phase 3 clinical study for COVID-19, as a potential treatment for the Omicron variant (B.1.1.529).

December 3, 2021
·
6 min read
Peptide Synthesis Market Size To Reach USD 516.75 Million in 2028, Says Reports and Data

Development of technologically advanced peptide synthesizers and availability of various peptide synthesis reagents are driving market revenue growth.

December 3, 2021
·
6 min read
Biotech Bay

Encoded Therapeutics Presents Data Showing That Children With Dravet Syndrome Experience Early, Substantial Neurodevelopment Deficits and Seizure Burden, at the American Epilepsy Society 2021 Annual Meeting

Encoded Therapeutics today announced initial findings from its ENVISION natural history study of children living with SCN1A+ Dravet syndrome, a rare developmental and epileptic encephalopathy.

December 3, 2021
·
6 min read
BioCapital

Emerging Omicron Variant Reinforces the Role of Rapid Antigen Testing

Ellume has conducted an assessment of the new Variant of Concern, Omicron, using the available genome sequencing data, and is highly confident that the Ellume COVID-19 Home Test will detect this new variant.

December 3, 2021
·
5 min read
Drug Development

Kolon TissueGene To Expand Indications For TG-C

ACTIVITIES ARE UNDERWAY TO INITIATE US PHASE II IN HIP OSTEOARTHRITIS

December 3, 2021
·
3 min read
Job Trends

Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19, with the Government of Canada

Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that it has entered into a Supply Agreement with the Government of Canada for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of COVID-19.

December 3, 2021
·
6 min read
BioCapital

FDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns

Today, the U.S. Food and Drug Administration revised the emergency use authorization (EUA) of bamlanivimab and etesevimab (previously authorized for pediatric patients 12 years of age and older weighing at least 40 kilograms, or about 88 pounds), to additionally authorize bamlanivimab and etesivimab administered together for the treatment of mild to moderate COVID-19 in all younger pediatric patients.

December 3, 2021
·
4 min read